Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Flu vaccine mystery: why some shots work better than others

NCT ID NCT07240922

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how getting the flu vaccine year after year changes your body's immune response. Researchers are testing two types of flu vaccines—a nasal spray (FluMist) and a shot (Flublok)—in 600 adults aged 22 to 50 in Hong Kong. They will measure antibodies and immune cells in the blood and nose to understand why some people get better protection than others.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Live attenuated influenza vaccine (FluMist) and recombinant hemagglutinin influenza vaccine (Flublok)
What this could lead to
If successful, this could help explain why some people respond better to flu vaccines than others, potentially leading to more effective vaccination strategies.
What could go wrong
This is a phase 4 study focused on immune response measurements, not on preventing flu itself. Results may not directly improve vaccine effectiveness or apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Oct 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 22-50 years at enrolment. 2. A. Participated in the DRIVE I or DRIVE II studies (for DRIVE IIIa). OR B. Did not participate in the DRIVE I or DRIVE II study (for DRIVE IIIb) and has not received influenza vaccination in the prior two years. 3. Capable of providing informed consent. 4. Resident in Hong Kong in the coming 2 years. Exclusion Criteria: 1. Included in one of the priority groups to receive influenza vaccination in Hong Kong (priority groups include pregnant women, long-stay residents of institutions for persons with disability, persons with chronic medical problems (chronic cardiovascular, lung, metabolic or kidney diseases, obesity (body mass index 30 or above) and chronic neurological condition ), healthcare workers or persons working in poultry, pig farming or pig slaughtering industry). 2. With diagnosed medical conditions related to their immune system. 3. Currently taking medication for any condition that impairs immune system. 4. Individuals who report medical conditions not suitable to receive inactivated influenza vaccines, such as: * Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine; or to a vaccine component; * Moderate or severe acute illness with or without fever after any previous influenza vaccination; or * A history of Guillain-Barré syndrome (GBS) within 6 weeks of previous influenza vaccination. 5. Individuals who report medical conditions not suitable to receive live attenuated vaccines, such as: * having asthma; * having close contact with severely immunosuppressed persons who require a protected environment; or * having immunosuppressive treatment (e.g. high-dose steroid, anti-cancer drugs and radiotherapy). 6. Individuals who report medical conditions not suitable to receive intramuscular injection, such as * Bleeding disorders * Habitually taking anticoagulants (with the exception of antiplatelets such as aspirin). 7. Individuals who have any medical conditions not suitable to receive inactivated or live attenuated influenza vaccines as determined by a clinician.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • School of Public Health, The University of Hong Kong

    Hong Kong, Hong Kong, 00000, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.